ClinicalTrials.gov record
Terminated Phase 1 Interventional

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

ClinicalTrials.gov ID: NCT00933985

Public ClinicalTrials.gov record NCT00933985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia

Study identification

NCT ID
NCT00933985
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
22 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013
Last update posted
Apr 30, 2014

2009 – 2013

United States locations

U.S. sites
18
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294
Childrens Hospital of Orange County Orange California 92868-3874
Children's National Medical Center Washington D.C. District of Columbia 20010
Lurie Children's Hospital-Chicago Chicago Illinois 60614
Indiana University Medical Center Indianapolis Indiana 46202
Dana-Farber Cancer Institute Boston Massachusetts 02115
C S Mott Children's Hospital Ann Arbor Michigan 48109
University of Minnesota Medical Center-Fairview Minneapolis Minnesota 55455
Washington University School of Medicine St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Oregon Health and Science University Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224
St. Jude Children's Research Hospital Memphis Tennessee 38105
University of Texas Southwestern Medical Center Dallas Texas 75390
Baylor College of Medicine Houston Texas 77030
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00933985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2014 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00933985 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →